The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer

Abstract

Anaplastic thyroid cancer represents 1%–2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%–20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%–75%. Referral of patients for participation in clinical trials is needed.

Keywords:

• thyroid cancer
• emerging therapies
• anaplastic thyroid carcinoma
• chemotherapy
• radiotherapy

Introduction

Anaplastic thyroid cancer (ATC) represents 1%–2% of all thyroid tumors and is characterized by aggressive, local invasion and common distant metastases. Histologically, ATC is characterized by elevated mitotic rate and lymphovascular invasion.¹

All patients with ATC are classified by the American Joint Committee on Cancer as having stage IV disease (IVa, intrathyroidal tumors; IVb, gross extrathyroidal; IVc, distant metastases). It affects prevalently the female sex; the ratio 3:1 is lower than the papillary or follicular histotypes.¹

The peak incidence occurs during the sixth to seventh decades of life. Anaplastic carcinoma has a poor 5-year survival rate (0–25%). Based on epidemiological studies derived from the Surveillance, Epidemiology and End Results Database, the incidence of ATC has held steady in the United States during the period between 1973 and 2002.¹

Clinically, patients refer with growing neck mass, dysphagia, cough, neck pain, and dyspnea. ATC is believed to occur from a terminal dedifferentiation of previously undetected long-standing thyroid carcinoma (eg, papillary, follicular).

ATC has a genetic association with oncogenes C-myc, H-ras, and Nm23. Mutations in BRAF, RAS, catenin (cadherin-associated protein) beta 1, PIK3CA, TP53, AXIN1, PTEN, and APC genes have been found in ATC, and chromosomal abnormalities are common.^2,3 Figure 1 summarizes the main route of tumor progression and dedifferentiation.

Figure 1 The main route of tumor progression and dedifferentiation.

Abbreviations: FA, follicular adenoma; FTC, follicular tumor cell; PTC, papillar thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; PDTC/ATC, poorly differentiated anaplastic tumor cancer; PPFP, paired box gene 8-peroxisome proliferator activated receptor; PI3K, phosphoinositide 3 kinase; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen activated kinases; RET, rearranged during transfection; AKT, alpha serine/threonine-protein kinase.

Preoperative cervical ultrasonography can detect lymph node metastases. Cervical computed tomography scanning can be used to define the local spread of disease. Detection of distant metastases to the mediastinum, lung, liver, bone, and brain is also possible, via computed tomography scanning or MRI. Bone scanning can be used to determine the presence of bone metastases. Positron emission tomography with ¹⁸F-fluorodeoxyglucose can be successfully used in ATC to detect lymph node metastases, lung metastases, and other distant metastases. Fine needle aspiration often yields enough cytological information to allow diagnosis, but sometimes an open surgical biopsy is required. Grossly, ATC is a large, fleshy, off-white tumor. Infiltration of adjacent structures can be observed grossly and microscopically. Histologically, the tumor may contain regions of spontaneous necrosis and hemorrhage. Typically, vascular invasion is detectable.^1–73

The main histological variants include spindle cell, giant cell (osteoclast-like), squamous, and pauci-cellular. The giant cell subtype typically exhibits local calcification with significant osteoid formation. The pauci-cellular subtype demonstrates rapid growth, intense fibrosis, focal infarction, diffuse calcification, and encroachment of adjacent vascular tissue by atypical spindle cells.⁴

Thyroid lymphoma is the only curable condition that may be confused with ATC. It is fundamental to rule out lymphoma in the presence of a poorly differentiated large cell thyroid tumor. This investigation involves lymphoid tissue markers (eg, cytoplasm immunoglobulin, immunoglobulin receptors, and gene rearrangement studies). When the tumor is surgically resectable, a tracheostomy is often required because of compression of the trachea. Total thyroidectomy is effective in reducing local symptoms produced by the tumor mass. However, surgery alone is not able to control the disease, even in patients with small intrathyroidal masses.¹

Radiotherapy (RT) is used to improve loco-regional control (LRC), often with chemotherapy (CT). External RT, up to 65 Gy, may slow the progress of the disease but rarely controls it. ATC has a rapid course and early dissemination.²⁰ The most common sites of distant spread include, in descending order, the lung, bone, and brain. Metastases, particularly in the lung, are likely to be present at diagnosis more than fifty percent of the time.⁷³

CT is often added concurrently with RT but appears to have a limited effect on survival in most studies.^10,21,37

Some studies report better LRC when RT and CT are administered in a preoperative setting. Whether surgery should be given upfront or after neoadjuvant treatment is an open issue.

However, both the heterogeneity of retrospective series and the absence of randomized trials do not allow recommendation of a standard treatment. Recently, the publication of guidelines by the American Thyroid Association (ATA)⁷⁴ taskforce on ATC offered a significant direction in the management of this disease.

In the last few years, biologically targeted therapies for advanced thyroid carcinomas have been proposed on the basis of the recognition of key oncogenic mutations. New treatments are needed for this highly aggressive malignancy.

This review will analyze ATC molecular characteristics, preclinical studies results and clinical management, and discuss possible emerging therapies.

Material and methods

A comprehensive literature review was finalized in February, 2013. Medline® was used for research. Electronic search results were supplemented by hand searching of selected papers, expert consensus meeting notes, and reference lists from selected articles. The literature search was limited to articles in English and humans. The following medical subject heading terms were used in the search: thyroid cancer, emerging therapies, anaplastic thyroid carcinoma, chemotherapy, radiotherapy. We analyzed and discussed the literature, taking into account the previously reported reviews on this matter. In short, we analyzed data from: 29 preclinical studies on genetic ATC alterations and target therapies, 14 clinical reviews, and 38 clinical studies, of these only 17 were prospective studies (see Tables 1 and 2).

Table 1 Treatment of anaplastic thyroid cancer

Series	Year	No	Therapies	Outcomes	Notes
Voutilainen et al^Citation23	1999	33	S → CRT	1-y DSS = 9.7% (CI: 2.0–25.9)	Resectability (P = 0.0002), metastases (P = 0.0014), RT (P = 0.014), and radioiodine ablation (P = 0.039) = PrF
Tan et al^Citation24	1995	21	S → RT ± CT	mOS = 4.5 m After radical S, mOS = 131 m	T > 6.0 cm (P = 0.004) and female (P = 0.02) = PrF
Pierie et al^Citation84	2002	67	S → RT ± CT	1-y OS = 92%a 3-y OS = 83%a After debulking: 1-y OS = 35% 3-y OS = 0% After no resection: 1-y OS = 4% 3-y OS = 0% (P < 0.0001)	Better OS for RT > 45 Gy than <45 Gy (P = 0.02) – Age ≤70 y – Absence of dyspnea or dysphagia at presentation, T ≤ 5 cm, and surgery (P < 0.05)
Schlumberger et al^Citation26	1991	20	<65 y → doxorubicin (60 mg/m^2) + cisplatin (90 mg/m^2) + RT >65 y → mitoxantrone (14 mg/m^2) + RT	OS > 20 m in 3/20 patients	Multimodal treatment improves OS and LRC. Gross tumor resection should be performed whenever possible
Mitchell et al^Citation27	1999	17	RT twice daily, DT 60.8 Gy	5/17 CR, 7/17 PR, 5/17 SD	High toxicity from esophagitis and dysphagia RR to RT but toxicity was unacceptable
Besic et al^Citation28	2005	188	S → CT ± RT	mOS = 3 m 1-y OS = 13% 2-y OS = 6%	Age, PS, tumor growth, tumor extension, and distant metastases = independent PrF
De Crevoisier et al^Citation29	2004	30	S→2 × CT → RT → 4 × CT CT = doxorubicin (60 mg/m^2) and cisplatin (120 mg/m^2)	3-y OS = 7% (95% Cl: 10%–44%) mOS = 10 m Death due to local PD in 5% and distant PD in 68%, and to both in 27%	Main toxicity was hematologic. High long-term OS with postop CRT
Brignardello et al^Citation22	2007	47	CRT → S → CT or S → CRT or CT		Maximal debulking followed by adjuvant CRT was the only treatment that modified OS (hazard ratio = 0.23, 95% CI: 0.07–0.79)
Haigh et al^Citation21	2000	33	CRT*/CRT* → S	OS = 3.8 m	Surgery improved outcome
Kobayashi et al^Citation30	1996	37	CRT* exclusively	NR	Main toxicity was hematologic. Some long-term OS with postop CRT
Swaak-Kragten et al^Citation31	2009	75	CRT*	1-y OS = 9%	LRC higher in R0/R1 resection or CRT, with best results with S + CRT (CR in 89%)
Vrbic et al^Citation32	2009	16	CRT**	ORR = 25% (95% CI: 7–55) OS = 11.0 m (95% CI: 8.56–13.44)	Long OS with Doxo + cisplatin
Yau et al^Citation33	2008	50	S S + T S + CRT	OS = 97 d	Age ≤65 (P ≤ 0.01), no metastatic disease at presentation (P < 0.01), surgery (P < 0.01), and postop RT = prF CT was not associated with longer OS
Lim et al^Citation34	2007	37	aRT	2-y LRC = 25% PFS = 8% OS = 18%	Better RR and LRC
Yau et al^Citation33	2006	15	S → RT	OS = 237 d	6, 12, 18, and 24-m OS = 33%, 26%, 13%, and 0%, respectively
Wang et al^Citation20	2006	47	SRT vs HRT	OS = 11 m	6-m LRC = 95% (P = 0.0001) with RT at 40 Gy vs 64% RT at <40 Gy. mOS with HRT: 13 m vs 10 m SRT (P = 0.3)
Veness et al^Citation25	2004	18	S + RT	OS = 6.2 m	Single modality correlates with worst prognosis
Haigh et al^Citation21	2001	33	S + RT	OS = 43 m (R0)	mOS = 3.3 m with only CT and RT and palliative resection (P = 0.63)
McIver et al^Citation36	2001	134	S → RT vs S	mOS = 3–5 m	Extent of resection did not affect survival (P > 0.4)
Besic et al^Citation28	2001	162	S → CRT CRT → S		1-y OS preop versus postop CRT (P = 0.17)
Heron et al^Citation38	2002	32	SRT aRT + CT***	2-y OS = 44% PFS = 53% 2-y OS = 52% PFS = 38%	HRT + CT is associated with better OS but not PFS
Nilsson et al^Citation39	1998	81	CRT*/CRT* → S	2-y OS = 90% OS = 4.3 m	OS > 2 y in 10% pts treated with CT + RT + S
Tennvall et al^Citation40	1994	33	aRT + doxorubicin + S	LF = 24%	Preop RT 30 Gy and postop RT 46 Gy + 20 mg doxo-weekly aRT > LRC
Junor et al^Citation41	1992	91	S + RT		Postop RT improve outcomes
Levendag et al^Citation42	1993	51	S + RT	OS = 7.5 m	Achievement of CR is an important goal of therapy
Derbel et al^Citation43	2011	44	S S + RT S + CRT RT	mOS of responders = 28.4 m; mOS of progressive = 5.1 m	mOS significantly lower in pts undergoing palliative surgery
Kim and Leeper^Citation10	1987	41	aRT + CT	CR = 84% LRC = 68% OS = 1 y	aRT + CT is feasible and achieves good response

Notes:

a After complete resection;

* doxorubicin;

** doxorubicin 60 mg/m² and cisplatin 40 mg/m² every 3 weeks;

*** doxorubicin, paclitaxel, vincristine, or cisplatin.

Abbreviations: T, tumor; PrF, prognostic factors (for OS); y, years; m, months; D, days; OS, overall survival; ORR, overall response rate; CI, confidence interval; LRC, loco-regional control; CRT, chemoradiation; CR, complete remission; aRT, altered fractionated RT; SRT, standard RT; HRT, hyperfractionated RT; R0, radically resected; Doxo, doxorubicin; DSS, disease specific survival; RR, response rate; CR, complete response; PR, partial response; SD, standard response; PS, performance status; PD, progressive disease; Preop, preoperative; Postop, postoperative; mOS, median overall survival; S, surgery; CT, chemotherapy; pts, patients; RT, radiotherapy; vs, versus; R1, resection indicated that the margins of the resected parts show tumor cells when viewed microscopically; CDDP, cisplatin.

Table 2 Most significant trials on molecular target therapies used in anaplastic thyroid cancer treatment

Study	Drug	Target	Phase	Outcome
Kim et al^Citation44	Aee788	EGFR VEGFR	P**	Increase apoptosis, inhibit cell proliferation
Fury et al^Citation51	Gefitinib	Multikinase	Phase I	Growth inhibition
Gupta-Ambramson et al^Citation53	Sorafenib	Multikinase	Phase II–III	Growth inhibition
Jin et al^Citation77	AZD6244 + everolimus	MEK inhibitors + mTOR inhibitor	P**	60% growth inhibition with combined MEK and mTOR inhibition
Rosove et al^Citation59	PLX4720	BRAF inhibitors	Case report	^18F-FDG–PET and computed tomography of the chest on day 38 showed nearly complete clearing of metastatic disease
Catalano et al^Citation16	VPA	Deacetylase inhibitors	Phase II	Enhance chemo-sensitivity and radio-sensitivity
Gule et al^Citation56	Vandetanib	Cellular matrix	P**	66%–69% growth inhibition
Cohen et al^Citation52	Axitinib	Multikinase	Phase II	Median PFS = 18.1 m. Decreased sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT
Liu and Xing^Citation8	MK2206	PI3K inhibitors	P**	Growth inhibition
Catalano et al^Citation78	Panobinostat	Deacetylase inhibitor	P* and P**	Significant reduction of Ki67 reduce tumor volume and growth
Papewalis et al^Citation79	Everolimus	mTOR inhibitor	P**	Growth inhibition
Nehs et al^Citation70	PLX4720	BRAF inhibitors	P*	Neoadjuvant PLX4720 could be an effective therapeutic strategy for early anaplastic thyroid cancers that harbor the BRAF(V600E)
Savvides et al^Citation71	Sorafenib	Multikinase	Phase II	10% PR 25% stable disease: PFS = 1.9 m, mOS = 3.9 m, 1-y survival OS = 20%
Cooney et al^Citation75	Combretastatin	Tubulin binding vascular disrupting agent	Phase II	33% DCR 1 patient had 30 m PFS
Ha et al^Citation76	Imatinib	Multikinase	Phase II	DCR 75%
Sosa et al^Citation83	Combretastatin	Multikinase	Phase III	mOS = 5 m

Notes:

* Orthotopic mouse model;

** ATC cell lines.

Abbreviations: P, preclinical; mTOR, mammalian target of rapamycin; PR, partial response; SD, stable disease; m, months; OS, overall survival; DCR, disease control rate; PFS, progression free survival; EGFR, epidermal growth factor receptor; VEGFR, vascular endothelial growth factor receptor; MEK, mitogen activated kinases; PI3K, phosphoinositide 3 kinases; mOS, median overall survival; ¹⁸F-FDG–PET; ¹⁸F-fluorodeoxyglucose positron emission tomography; VPA, valproic acid; s, serum.

Molecular characteristics

Anaplastic cells do not express thyroid-specific genes; they do not produce thyroglobulin, are unable to transport iodine; and thyrotropin receptors are not found on their plasma membranes.

ATC has a more complex and less distinct gene profile than papillary and follicular cancer, and molecular data suggests it may de-differentiate from well-differentiated thyroid cancer (WDTC). In about one-third of ATC cases, probably those arising from pre-existing papillary differentiated thyroid cancer (PTC), the BRAF(V600E) mutation (2–3) is present. It is also suggested that ATC might develop from RAS-mutated follicular thyroid cancer (FTC), since RAS mutation is also detected in 6%–50% of ATC.² The refractory nature of ATC to therapy may occur, at least in part, due to the presence of cancer stem cells, which have been identified in ATC cell lines.⁶³

In ATC, a mutation of PIK3CA gene causing AKT and ERK activation was reported.^3,4,68 Many of the genetic alterations found in ATC could potentially activate both the MAPK and PI3K/AKT pathways, including RTK gene copy gain, RET/PTC, and RAS mutations. Figure 2 schematizes some of the most important pathways.

Figure 2 Anaplastic thyroid cancer growth pathways.

Note: The MAPK/ERK/PTEN pathway is a chain of proteins that communicates a proliferation signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.
Abbreviations: MAP, Mitogen-activated protein; ZO, zonula occludens; MAPK, MAP kinase; mTOR, mammalian target of rapamycin; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositide 3 kinase; RET, rearranged during transfection; EGFR, epidermal growth factor receptor; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; PIP, phosphatidylinositol phosphate; PTC, papillary thyroid cancer; AKT, alpha serine/threonine-protein kinase; PTEN, phosphatase and tensin homolog; P, phosphate; PCL, phospholipase C.

The BRAF mutation, which can activate the MAPK pathway, commonly coexisted with genetic alterations that could activate the PI3K/AKT pathway (eg, the PIK3CA copy gain) in ATC. AKT1 was activated in most ATC cases (85%–93%),^5,6 and ERK was activated in 65%.⁶ Phosphatase and tensin homology encoding chromosome 10 (PTEN) negatively regulates the PI3K pathway, and was mutated in 17% of 48 cases.^7,8

Aurora kinases play an important role in cell division, and deregulation may result in aneuploidy. Aurora B is overexpressed in ATC cell lines,⁹ and patient samples had a marked increase when compared with normal thyroid tissue or PTCs.⁹ Like aurora B, aurora A is overexpressed at both the mRNA and protein levels in ATC cell lines, while aurora C is increased only at the protein level.⁸

Genetic alterations or their combinations that could activate both the MAPK and PI3K/AKT pathways were found in up to 81% cases of ATC.⁷

PIK3CA/AKT1 mutations and PIK3CA copy gain are frequently identified in ATC, as compared to well differentiated cancer, suggesting that PI3K/mTOR pathway activity is involved in the process of cancer de-differentiation.⁷⁰

Additional mutations frequently observed in ATC involve p53 and β-catenin. The tumor-suppressor gene p53 is fundamental for the progression from indolent to aggressive thyroid cancer. The inactivating p53 mutation, seldom detected in WDTC, is found in about 55% of PTC and ATC.² Membrane β-catenin expression is progressively reduced with loss of tumor differentiation, resulting in tumor invasiveness, and increasing metastatic potential.⁵

Treatments

Treatment of ATC has ranged from surgery, radiotherapy, chemotherapy, or a combination of these regimens. Any modality used alone usually fails to control local disease, which is often the cause of death. Complete resection of ATC in the neck usually is not possible, but surgery can be an effective palliative modality. Extensive radical neck operations with en bloc adjacent organ resection are associated with high morbidity and are probably not warranted for this disease.⁶¹ Postoperative RT, as well as palliative RT is widely used.

Agents used for chemotherapy usually include doxorubicin and analogs, but paclitaxel, cisplatin, carboplatinum, VP-16, cyclophosphamide, melphalan, and bleomycin are also used.

However, no standards of care for ATC are approved.

This depends on the lack of few statistically significant data in this population. Additionally, due to the rarity of the disease, few patients are enrolled in clinical trials. ATA recommends a comprehensive multimodality plan to establish treatment strategy.

Radiotherapy

Radiotherapy for ATC has changed from palliative low dose of standard RT to altered fractionation RT (hyper fractionation) and higher dose (>40 Gy). Since ATC is a rapidly dividing tumor, hyperfractionated RT or the combination of CRT minimizes tumor cell repopulation. External beam RT to the neck or mediastinum was administered to total doses ranging from 45–75 Gy.¹

Wang et al (2006) demonstrate the importance of a radical dose of radiotherapy: ie, patients with good performance status and no distant metastases who received radical radiotherapy (>40 Gy) versus [vs] those with poor performance status or distant metastases, had a median survival of 11.1 and 3.2 months, respectively.²⁰

High dose accelerated RT improves the response rate to RT but toxicity is hardly manageable. Hyperfractionated RT seems to be more effective for local control than conventional treatment.²⁷

Several authors have assessed the efficacy and feasibility of postoperative radiotherapy. Higher locoregional control is associated with accelerated RT and free surgical margins.⁴⁰

Chemotherapy and chemoradiotherapy

Doxorubicin was considered the most effective drug for ATC until a few years ago. In a randomized study of ECOG, the combination of cisplatin and doxorubicin was shown to be more effective than doxorubicin alone, with higher complete RR.

Combination chemotherapy with bleomycin, doxorubicin, and cisplatin resulted in a response rate of 40% in advanced thyroid cancer, producing considerable palliative effects. It is noteworthy that best responses to this regimen were observed often in patients with ATC.¹¹ Several other reports confirmed that a combination CT versus doxorubicin alone is more effective (RR 5% vs 18%).¹⁷

Preclinical studies showed that paclitaxel inhibited growth in multiple ATC cell lines,¹³ causing cell cycle arrest, apoptosis, and phosphorylation of multiple signaling kinases (JNK, ERK, AKT1).¹² Based on preclinical data, an open-label Phase II clinical trial of paclitaxel as a 96-hour infusion was conducted, achieving a favorable outcome: overall response rate (ORR) = 53%, disease progression (DP) = 42%, stable disease (SD) = 5%, partial regression (PR) = 47%, or complete regression (CR) = 5%; overall survival (OS) = 6 m, median survival (mOS) = 7 and 32 weeks in responders and non-responders respectively.¹⁴

Long-term survivors were also reported among patients with stage IVb and IVc disease using weekly paclitaxel administration as induction CT,¹⁵ while no significant OS difference was assessed among stage IVc patients.¹³

The paclitaxel effects on apoptosis and tubulin acetylation are both enhanced by the histone deacetylase inhibitor, valproic acid.¹⁶

Inhibition of cell cycle progression is an important strategy for reducing tumor growth: in ATC cell lines, gemcitabine, a nucleoside analog, induces G1/S arrest. The cytotoxic effect is additive if followed by cisplatin. Of interest, these drugs produce an antagonistic response when given in reverse order, as cisplatin inhibits gemcitabine incorporation into DNA.¹²

Chemotherapy improved the effect of RT in locoregional and distant control. Weekly administration of low-dose doxorubicin concurrently with RT showed an acceptable toxicity and may be a therapeutic option for patients with ATC (2-y LRC: 68%; mOS: 1 y).¹⁰

Haigh et al²¹ reported the results of resected patients treated with CRT; with 8/26 patients being long survivors after postoperative CRT. In patients treated with potentially curative resection, median survival was 43 months compared with 3 months with palliative resection (P < 0.002).²¹

No association was found between survival and age, prior goiter, prior thyroid carcinoma, adjacent differentiated carcinoma, or tumor size.

Table 1 reports some of the most impressive studies using RT and CT therapies in ATC.

In Turin, Italy, 27 patients were treated in a 5-year period.²² Surgery was performed initially (maximum debulking in 11 and palliative in 6). Chemotherapy (doxorubicin + cisplatin) was given during and after radiation. The approach in five patients was neoadjuvant CRT followed when possible by surgery, while five others had paclitaxel therapy alone. As in other series, surgical resection was the major contributor to patient responses. While median survival was only 3.9 months, those with maximal debulking had a 6-month survival of 58%; those with palliative or no surgery, only 10%.²²

Akaishi et al reported a retrospective series of 100 patients with ATC, treated between 1993 and 2009. Patients received surgery followed by RT with or without CT. Nineteen of the 100 patients survived for more than 1 year, and most of these underwent a complete resection, as opposed to debulking, followed by adjuvant radiotherapy with or without chemotherapy. However, the overall survival at 2 years remains dismal (12.3%).³⁷

Emerging therapies

There is a growing interest in target therapies and preclinical findings, in order to improve the dismal results obtained with conventional chemotherapy and chemoradiation in ATC.

Much has been learned about the genes, RNAs, and proteins deregulated. A lot of new drugs have been investigated but only few were demonstrated to be effective in both preclinical and clinical investigations.^79–82

EGFR inhibitors

The frequent presence of endothelial growth factor receptor (EGFR) in ATC tumors and pleiotropy of its effects makes it an attractive target for drug development. Gefitinib, a tyrosine kinase inhibitor, slows down cell growth, although high doses are necessary in ATC cells. Early stage clinical trials have been performed in combination with docetaxel but results are dismal.^45,46

The monoclonal antibody cetuximab should induce apoptosis but evidence for this is conflicting.^46,47 In preclinical trials, Kim et al⁸⁵ observed that combination therapy with cetuximab/irinotecan inhibits the growth and progression of orthotopic ATC in nude mice.

An interesting dual inhibitor of EGFR and vascular EGFR (VEGFR), AEE788, was shown in ATC cells to increase apoptosis and inhibit both cell proliferation and the phosphorylation of multiple proteins.^44,47 Kim et al (2005) showed that dual inhibition in combination with paclitaxel, is effective.⁴⁴

Multikinase inhibitors, mTOR inhibitors, MEK inhibitors, and other emerging therapies

Imatinib, another tyrosine kinase inhibitor with multiple targets, (eg, BCR-ABL1; c-KIT; PDGFR) has variable activity in ATC cell lines.^44–46 However, imatinib does not achieve its effects at clinically achievable concentrations, although a recent clinical trial in 11 patients achieved a disease control rate in 6, with 6-month PFS = 27% and 6-month OS = 46%.⁷⁵

Other agents that have shown cytostatic effects in preclinical settings are in the clinical phase of investigation, such as plitidepsin, TP53-expressing adenovirus, mammalian target of rapamycin (mTOR) inhibitors and thiazolidinediones (TZDs), MEK inhibitors (AZD6244), tubulin-binding agents, and combretastatin A.^48–50

Combretastatin A (CA4P) achieved satisfactory results in Phase II–III studies;⁷⁶ in the Phase III trial, its combination with carboplatin and paclitaxel showed a 35% reduction in the risk of death (1-y OS = 27% vs 9% with CT + CA4P vs CT respectively; P = 0.065).⁸³

Unsatisfactory results were obtained with axitinib and pazopanib monotherapy, even if an association of pazopanib and paclitaxel appears promising.^52,53 Nevertheless, most of these trials with targeted agents were based on limited numbers of patients; therefore, all interesting results should be confirmed.

However, at the 2012 Italian Oncology Meeting, Spallanzani et al presented experience from Modena University Hospital with TKIs: 9 patients treated with sunitinib (7 patients) and sorafenib (2 patients) confirmed the efficacy and safety profile of TKIs in ATC.⁵⁸

A Phase II study of sorafenib in ATC patients⁷¹ and an international multicenter Phase III trial of sorafenib versus placebo in patients with iodine-refractory thyroid cancer (NCT00984282)⁷² are ongoing.

Given the genomic instability of ATC, effective therapies may benefit from comprehensive microarray analysis or genome-wide screening to develop an individualized therapeutic regimen that maximally inhibits major pathways at multiple genetic and epigenetic levels. In addition, to more fully characterize the complex molecular profile, subsequent rapid in vitro screening assays of combinations of targeted therapies may further optimize a patient’s treatment plan. Finally, refinement may derive from evolving drug delivery systems such as nanoparticles.^63,64

Recently valproic acid (VPA) was investigated in preclinical studies and showed highly efficacy in suppressing the growth of poorly differentiated thyroid cancer cell lines, inducing apoptosis and cell cycle. Its activity is limited in VPA monotherapy but it may be added to CT, as it enhances the cytotoxicity of doxorubicin and increases radiosensitivity.^16–44

Panobinostat (LBH589) is a hydroxamic acid with potent inhibitory activity at low nanomolar concentrations against all classes of histone deacetylases (pan-deacetylases inhibitor).^55–80

In vitro treatment with LBH589 resulted in impairment of cell viability, inhibition of colony formation, cell cycle arrest, and apoptosis induction. Recently, it has been reported that two histone deacetylase inhibitors, trichostatin A and vorinostat, induced miR-129-5p overexpression, histone acetylation, and cell death in papillary and anaplastic cancer cell lines, and in primary cultures of papillary thyroid cancer.

Disruption of the E-cadherin/catenin complex contributes to tumor metastasis, and decreased expression of E-cadherin is observed in advanced stage, poorly differentiated carcinomas, and is associated with the transformation of differentiated carcinomas. Loss of E-cadherin is associated with the transformation in ATC.⁶⁹

Wunderlich et al⁵⁷ reported that vandetanib inhibited tumor growth of the ATC cell lines in vivo (Hth83 and 8505C by 69.3% [P < 0.001] and 66.6% [P < 0.05], respectively), when compared to control. The authors concluded that the tremendous in vivo anti-tumor activity of vandetanib against ATC makes it an attractive candidate for further preclinical as well as clinical development for the treatment of this particularly virulent cancer, which remains effectively untreatable.⁵⁷

Inhibition of the proteasome pathway with bortezomib is also a strategy to evaluate in in-vivo experiments, as it showed proapoptotic activity on ATC.⁵⁸

Aurora kinases inhibitors (MLN8054) had proapoptotic and antiproliferative effects in ATC cells. The antitumoral activity is increased with the association of bortezomib.⁸³

Another critical serine-threonine protein kinase involved in the MAPK pathway that has been targeted to block its constitutive kinase activation is BRAF.^66,67

BRAF mutation (V600E) is reported in 24% of papillary-derived ATC. Preclinical and clinical studies investigating combination therapy with agents such as selective (PLX4032) and potent (BAY 73-4506 and ARQ 736) small-molecule BRAF inhibitors, and MAP/ERK kinase inhibitors (AZD6244) hold great promise in the treatment of BRAF(V600E) ATC.^65,66,68

In a mouse model, the BRAF inhibitor PLX4720 suppressed growth of mutated human anaplastic thyroid cancer. A case report by Rosove et al was recently published in the New England Journal of Medicine.⁵⁹

PI3K/mTOR inhibitors are also under investigation at different levels of clinical studies. For example, BEZ235 reduces PI3K and mTOR kinase activity by competitive binding to the ATP-binding cleft of these enzymes.^67,69,70,79

Table 2 reports the most significant trials on molecular target therapies used in ATC treatment.

Conclusion

The outcome after treatment of ATC remains disappointing. However, knowledge about management of anaplastic tumors is increasing, and this information must be shared to improve outcomes. Indeed, this tumor was neglected by oncologists, and many doctors are still not informed about treatment options, in particular, drugs. The weakness of these studies on novel targeted agents is low accrual in clinical trials, also due to the rarity of the disease and its rapid evolution.

A multimodality approach should represent the standard treatment of choice in ATC, with surgery being the cornerstone of management of early stage patients. Notably, surgery remains the most important treatment modality when a complete resection may be obtained.

The role of preoperative or postoperative CRT remains controversial, although the use of both surgery and chemoradiation correlates with a better outcome.

A major concern of CRT is toxicity, which negatively impacts the completion of protocol. However, it improves both local and distant control, although it appears recommendable mostly for fit patients.

Because ATC management is very challenging, researchers look at emerging target therapies with a lot of interest. However, although there are promising results in preclinical development, only few studies on new molecules have been clinically confirmed. Clearly, a better understanding of the molecular pathogenesis driving the disease is required to define new therapeutic strategies. This knowledge might provide useful drugs to be used both alone or in combination with conventional methods. In short, the hope of a novel treatment strategy comes from unsatisfactory results from conventional therapies. An effort of every institution to allow clinical trials participation is required.

Confirmatory data from these new therapeutic strategies are needed.

Acknowledgments

The authors express thanks to Lawrence Preston for copy-editing, and Lega Italiana Tumori, Sezione di Cuneo for fundraising.

Disclosure

The authors report no conflicts of interest in this work.